Cinryze®

Understanding Cinryze®

Cinryze® is a plasma-derived therapy used to prevent hereditary angioedema (HAE) attacks in both adults and children. HAE is a rare genetic disorder that causes recurrent episodes of severe swelling in various parts of the body, including the face, hands, feet, airway, and digestive tract. Cinryze® is a lifelong therapy designed for HAE patients who experience frequent or severe attacks and require consistent prevention to effectively manage their condition.

How Cinryze® Works:

• Replaces deficient or malfunctioning C1 esterase inhibitor (C1-INH) in patients with HAE.
• Prevents excessive swelling by regulating the complement and kallikrein-kinin systems.
• Reduces attack frequency and severity, helping to maintain a better quality of life.

FDA Approval:

• Cinryze® (C1 esterase inhibitor [human]): Approved in 2008.

For more information, please visit the Cinryze® patient website and speak with your healthcare provider to determine if Cinryze® is the right treatment option for you.